BTK Inhibitors for B-Cell Lymphomas: A Summary Resource

Download this online resource developed to serve as a helpful guide for healthcare professionals on BTK inhibitors in B-cell lymphoma.
Format: Adobe Acrobat (.pdf)
File Size: 235 KB
Released: January 4, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Atara Biotherapeutics, Inc.
Bayer HealthCare Pharmaceuticals Inc.
BeiGene, Ltd.
Epizyme
Genentech, a member of the Roche Group
Genmab US, Inc.
Incyte Corporation
Karyopharm Therapeutics
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Related Content

A video on providing respectful healthcare for transgender persons as illustrated through the personal transition story of Pharmacist Olivia Buckoski, from Clinical Care Options (CCO)

Olivia Buckoski, PharmD Released: May 25, 2022

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on best practices for molecular testing of targetable biomarkers in advanced NSCLC (May 2022), from Clinical Care Options (CCO)

Released: May 24, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings